The potential for immunoconjugates in lymphoma therapy

Hematology/Oncology Clinics of North America

Volumn 11, Issue 5, 1997, Pages 987-1006

  Liu, S Y ^a   Press, O W ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; DIPHTHERIA TOXIN; IDIOTYPIC ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY Y 90; PSEUDOMONAS EXOTOXIN; RICIN A;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; DRUG SCREENING; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0030930350     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70475-5     Document Type: Article

References (69)

1. P. Amlot M. Stone D. Cunningham A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy Blood 9 1993 2624
2. M. Beckwith R. Fenton I. Katona Phosphatidylinositol-3-kinase activity is required for the anti-Ig-mediated growth inhibition of human B-lymphoma cell line Blood 87 1996 202
3. M. Beckwith W. Urba Ferris Anti-IgM–mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation J Immunol 147 1991 2411
4. S. Brown R. Miller S. Horning Treatment of B-cell lymphoma with anti-idiotype antibodies alone and in combination with alpha interferon Blood 73 1989 651
5. S. Brown R. Miller R. Levy Antiidiotype antibody therapy of B-cell lymphoma Semin Oncol 16 1989 199
6. M. Czuczman D. Straus C. Divgi Phase I dose escalation of Iodine-131–labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma J Clin Oncol 11 1993 2021
7. Daly D, Fussell J, Milejski P, et al: Interim results of the European multi-centre phase II study of CAMPATH-1H in non-Hodgkin's lymphoma (NHL) (including chronic lymphocytic and prolymphocytic leukaemia (CLL, PLL) (protocol 125-005-C92). Proceedings of the Eleventh International Hammersmith Conference on Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, 1994
8. C. Demanet J. Brissinck M. Van Mechelen Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype and anti-CD3) J Immunol 147 1991 1091
9. R. Dillman D. Shawler J. Dillman Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody J Clin Oncol 2 1984 881
10. M. Dyer G. Hale F. Hayhoe Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype Blood 73 1989 1431
11. A. Frankel D. Fitzgerald C. Siegall Advances in immunotoxin biology and therapy: A summary of the fourth international symposium on immunotoxins Cancer Res 56 1996 926
12. K. Fujimori D. Covell J. Fletcher A modeling analysis of monoclonal antibody percolation through tumors: A binding site barrier J Nucl Med 31 1990 1191
13. D. Goldenberg J. Horowitz R. Sharkey Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131–labeled LL2 monoclonal antibody J Clin Oncol 9 1991 548
14. M. Grossbard A. Freedman J. Ritz Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion Blood 79 1992 576
15. M. Grossbard J. Gribben A. Freedman Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma Blood 81 1993 2263
16. M. Grossbard J. Lambert V. Goldmacher Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms J Clin Oncol 11 1993 726
17. M. Grossbard S. O'Day J. Gribben A phase II study of anti-B4-blocked ricin (anti-b4-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL) Proc Am Soc Clin Oncol 13 1994 293
18. M. Grossbard O. Press F. Appelbaum Monoclonal antibody–based therapy of leukemia and lymphoma Blood 80 1992 863
19. G. Hale M. Clark R. Marcus Remission induction in non-Hodgkin's lymphoma with a reshaped human monoclonal antibody campath-1H Lancet 2 1988 1394
20. A. Hekman A. Honselaar W. Vuist Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody Cancer Immunol Immunother 32 1991 364
21. A. Hertler D. Schlossmann M. Borowitz An anti-CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin-monensin Int J Cancer 43 1989 215
22. E. Hu A. Epstein G. Naeve A phase Ia clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies Hematol Oncol 7 1989 155
23. P. Jones P. Dear J. Foote Replacing the complementarity-determining regions in a human antibody with those of a mouse Nature 321 1986 522
24. M. Juweid R. Sharkey A. Marlowitz Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 55 1995 5899
25. M. Kaminski L. Fig K. Zasadny Imaging, dosimetry, and radioimmunotherapy with iodine-131–labeled anti-CD37 antibody in B-cell lymphoma J Clin Oncol 10 1992 1696
26. M. Kaminski K. Zasadny I. Francis Iodine-131–anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 14 1996 1974
27. 131I anti-B1 (anti-CD20) antibody N Engl J Med 329 1993 459
28. S. Knox M. Goris K. Trisler Yttrium-90–labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res 2 1996 457
29. S. Knox R. Hoppe D. Maloney Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody Blood 87 1996 893
30. T. Kuzel F. Foss C. Lemaistre Phase I trial of diphtheria toxin (DT) fusion protein (DAB389 IL-2) for the treatment of interleukin-2 receptor (IL-2R) expressing hematologic neoplasm Blood 86 1995 274a
31. J. Lambert G. McIntyre M. Gauthier The galactose binding sites of the cytotoxic ricin an be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides Biochemistry 30 1991 3234
32. C. LeMaistre A. Deisseroth B. Fogel Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma Blood 78 1991 1173
33. C. LeMaistre C. Meneghetti M. Rosenblum Phase I trial of interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor Blood 79 1992 2547
34. J. Lewis G. DeNardo S. Denardo Radioimmunotherapy of lymphoma: A UC Davis experience Hybridoma 14 1995 115
35. D. Maloney S. Brown D. Czerwinski Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype negative variant cells Blood 80 1992 1502
36. D. Maloney A. Grillo-Lopez D. Bodkin IDEC-C2B8 anti-CD20 antibody: Results of long term follow-up of relapsed NHL phase II trial patients Blood 86 1995 54a
37. D. Maloney T. Liles D. Czerwinski Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 1994 2457
38. D. Matthews F. Appelbaum J. Eary Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque Blood 78 1991 1864
39. P. McLaughlin A. Grillo-Lopez M. Czuczman IDEC-C2B8 (rituximab): Clinical activity in clinically chemoresistant (CCRD) low grade or follicular lymphoma (LG/F) and in patients (pts) relapsing after anthracycline therapy (ANTHRA-RX) or ABMT Proc Am Soc Clin Oncol 16 1997 16a
40. T. Meeker J. Lowder Maloney A clinical trial of anti-idiotype therapy for B cell malignancy Blood 65 1985 1349
41. T. Meeker J. Lowder M. Cleary Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotypic antibodies N Engl J Med 312 1985 1658
42. R. Miller D. Maloney R. Warnke Treatment of B cell lymphoma with monoclonal antiidiotype antibody N Engl J Med 306 1982 517
43. R. Miller A. Oseroff P. Stratte Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma Blood 62 1983 988
44. V. Oi S. Morrison Chimeric antibodies Bio-Techniques 4 1986 214
45. A. Osterborg M. Dyer D. Bunjes Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia J Clin Oncol 15 1997 1567
46. T. Philip J. Armitage G. Spitzer High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma N Engl J Med 316 1987 1493
47. O. Press F. Appelbaum J. Eary Radiolabeled antibody therapy of lymphoma V. DeVita S. Hellman S. Rosenberg Biologic Therapy of Cancer, Updates 4 1994 JB Lippincott Philadelphia 1 13
48. O. Press F. Appelbaum J. Ledbetter Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas Blood 69 1987 584
49. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 346 1995 336
50. O. Press J. Eary F. Appelbaum Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329 1993 1219
51. O. Press J. Eary F. Appelbaum Radiolabeled antibody therapy of lymphoma B. Dana Malignant Lymphomas, Including Hodgkin's disease: Diagnosis, Management and Special Problems 1993 Kluwer Academic Publishers Boston 127
52. Raubitschek A: Yttrium-90-labeled T101 in the treatment of hematologic malignancies. Proceedings of the Fifth International Conference on Monoclonal Antibody Conjugates for Cancer, 1990
53. M. Reff K. Carner K. Chambers Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435
54. L. Reichmann M. Clark H. Waldmann Reshaping human antibodies for therapy Nature 332 1988 323
55. 131I-labeled monoclonal antibody: An Illinois cancer council study J Clin Oncol 5 1987 562
56. E. Sausville D. Headlee M. Stetler-Stevenson Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cll lymphoma: A phase I study Blood 85 1995 3457
57. D. Scadden T. Doweiko Z. Bernstein Combined immunotoxin and chemotherapy for initial treatment of AIDS lymphoma Blood 84 1994 163a
58. R. Scheuermann E. Racila T. Tucker Lyn tyrosine kinase signals cell arrest but not apoptosis in B-lineage lymphoma cells Proc Natl Acad Sci USA 92 1995 75
59. R. Schroff K. Foon S. Beatty Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy Cancer Res 45 1985 879
60. D. Segal J. Wunderlich Targeting of cytotoxic cells with heterocrosslinked antibodies Cancer Invest 6 1988 83
61. D. Shawler R. Bartholomew L. Smith Human immune response to multiple injections of murine monoclonal IgG J Immunol 135 1985 1530
62. M. Stone E. Sausville J. Fay A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma Blood 88 1996 1188
63. M. Sznol J. Holmlund Antigen-specific agents in development Semin Oncol 24 1997 173
64. F. Uckun W. Evans C. Forsyth Biotherapy of B-cell precursor leukemia by targeting genistein to CD-19 associated tyrosine kinases Science 267 1995 886
65. E. Vitetta R. Fulton R. May Redesigning nature's poison's to create anti-tumor reagents Science 238 1987 1098
66. E. Vitetta M. Stone P. Amlot Phase I immunotoxin trial in patients with B-cell lymphoma Cancer Res 51 1991 4052
67. C. White S. Halpern B. Parker Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotype monoclonal antibodies Blood 87 1996 3640
68. T. Yokota D. Milenic M. Whitlow Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 52 1992 3402
69. A. Zimmer E. Kaplan J. Kazikiewicz Pharmacokinetics of I-131-T101 monoclonal antibody in patients with chronic lymphocytic leukemia Antibody, Immunoconjugate and Radiopharmaceuticals 1 1988 291